An open-label, Simon Phase II clinical trial of MRG003 in combination with PD-1 inhibitors for first-line treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 611f81c09eb60f63ef891801455b145b2c7d0503
First added on: Oct 10, 2026